Zymeworks Temettü
Temettü kriter kontrolleri 0/6
Zymeworks does not have a record of paying a dividend.
Anahtar bilgiler
n/a
Temettü verimi
-4.3%
Geri Alım Getirisi
| Toplam Hissedar Getirisi | -4.3% |
| Gelecekteki Temettü Verimi | 0% |
| Temettü Büyümesi | n/a |
| Bir sonraki temettü ödeme tarihi | n/a |
| Eski temettü tarihi | n/a |
| Hisse başına temettü | n/a |
| Ödeme oranı | n/a |
Son temettü güncellemeleri
Güncelleme yok
Recent updates
Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Nov 03
Time To Worry? Analysts Are Downgrading Their Zymeworks Inc. (NASDAQ:ZYME) Outlook
Nov 01Zymeworks Approaching A Moment Of Truth With Zanidatamab
Sep 27Analysts Are Betting On Zymeworks Inc. (NASDAQ:ZYME) With A Big Upgrade This Week
Aug 07Zymeworks Inc.'s (NASDAQ:ZYME) 27% Share Price Surge Not Quite Adding Up
Jul 26Zymeworks: A Somewhat Complicated Story
Jul 09Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans
Jun 12Zymeworks Inc.'s (NASDAQ:ZYME) Shares Lagging The Industry But So Is The Business
May 03Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data
Apr 18Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments
Mar 05Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion
Feb 06Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tailwind
Jan 31Zymeworks Non-GAAP EPS of -$0.66 beats by $0.31, revenue of $2.6M misses by $1.95M
Nov 08Zymeworks: A Binary Event With BTC Data By End-2022 Which May Trigger Milestone
Oct 26Zymeworks: A Roller Coaster Year
Jul 26Zymeworks And The Blue Falcon Elucidation
May 17Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: Insufficient data to determine if ZYME's dividends per share have been stable in the past.
Büyüyen Temettü: Insufficient data to determine if ZYME's dividend payments have been increasing.
Piyasaya Karşı Temettü Getirisi
| Zymeworks Piyasaya Karşı Temettü Getirisi |
|---|
| Segment | Temettü Verimi |
|---|---|
| Şirket (ZYME) | n/a |
| Pazarın Alt %25'i (US) | 1.5% |
| Pazarın En İyi %25'i (US) | 4.5% |
| Sektör Ortalaması (Biotechs) | 2.2% |
| Analist tahmini (ZYME) (3 yıla kadar) | 0% |
Önemli Temettü: Unable to evaluate ZYME's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Yüksek Temettü: Unable to evaluate ZYME's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: Insufficient data to calculate ZYME's payout ratio to determine if its dividend payments are covered by earnings.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as ZYME has not reported any payouts.